Quantcast
Last updated on April 18, 2014 at 5:48 EDT

Latest MicuRx Pharmaceuticals Inc. Stories

2013-12-20 00:20:36

-- Begins Phase 2 Clinical Study in China, Phase 1 Bridging Study in Australia -- HAYWARD, Calif. and SHANGHAI, Dec. 19, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus...

2013-08-22 04:21:55

-- Funds U.S. Development of MRX-I Next-Generation Antibiotic -- HAYWARD, Calif. and SHANGHAI, Aug. 22, 2013 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced it raised $25 million in Series B financing. Led by BVCF, a private equity and growth fund specializing in the life sciences industry, the round also includes existing investors Morningside Group and Devon Park Bioventures. Proceeds...

2012-10-24 07:32:22

HAYWARD, Calif. and SHANGHAI, Oct. 24, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, and Shanghai Zhangjiang Biomedical Industry Venture Capital today announced the establishment of Shanghai MengKe Pharmaceuticals, Inc., a joint venture formed to fund the development and commercialization of MRX-I for the Chinese market. MRX-I is a novel, oral oxazolidinone antibiotic targeting infections due to...

2012-05-22 22:21:01

HAYWARD, Calif., and SHANGHAI, May 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that the U.S. Patent and Trademark Office (USPTO) issued a composition of matter patent covering its clinical candidate, MRX-I. MRX-I is a novel antibacterial oxazolidinone that targets infections due to multi-drug resistant Gram-positive pathogens. "This patent is expected to be the first of a series to...

2012-04-22 22:20:49

HAYWARD, Calif. and SHANGHAI, April 23, 2012 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the completion of its Phase 1 clinical trial for MRX-I, its first development-stage antibiotic drug candidate. The agent MRX-I, an oral oxazolidinone antibiotic, targets infections due to multi-drug resistant Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and...

2010-04-06 14:00:00

HAYWARD, Calif. and SHANGHAI, April 6 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development of antibiotics to treat drug-resistant bacteria, and Cumencor Pharmaceuticals, Inc. today announced that the companies have entered a collaboration with Pfizer (NYSE: PFE) to discover novel therapeutic agents to treat multi-drug resistant tuberculosis (MDR-TB). Cumencor Pharmaceuticals is a China-based biotechnology company applying MicuRx's...

2010-03-15 07:00:00

HAYWARD, Calif. and SHANGHAI, March 15 /PRNewswire/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including...

2008-08-18 09:01:01

UNION CITY, Calif. and SHANGHAI, China, Aug. 18 /PRNewswire-FirstCall/ -- MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the nomination of MRX- I as its first preclinical development candidate. MRX-I is an antibacterial molecule targeting multi-drug resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Simultaneously, the company expanded its operations in China to...